Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy.
Rodgers S, Rees R C, Hancock B W·British journal of haematology
We have studied the properties of eosinophils from 26 patients with malignant melanoma and 16 patients with renal cell carcinoma (RCC) who were entered into a phase II clinical trial using various schedules of low-dose rhIL-2 immunotherapy. Eosinophilia was observed in 65% of melanoma patients and 100% of renal patient…